肺癌患者胸腔积液和外周血CD4+CD25+调节性T细胞与细胞因子表达及其意义的研究

目的：探讨肺癌患者胸腔积液及外周血CD4^＋CD25^＋调节性T细胞及其所分泌的细胞因子的特点及其临床意义。方法：采用流式细胞术和ELISA法检测32例肺癌患者胸腔积液及外周血CD4^＋CD25^＋调节T细胞水平、淋巴细胞亚群和TGF-β、IL-10以及IFN-γ的水平。结果：肺癌患者胸腔积液及外周血CD4^＋CD25^＋调节T细胞水平明显高于正常对照组（t=7．68，P=0．000；t=5．62，P=0．000），且胸腔积液高于外周血（t=2．05 P=0．002）；肺癌患者胸腔积液及外周血CD4、CD4／CD8、CD56阳性细胞比例明显低于正常对照组（t=7．51，P=0．000；t=3．63，P=0．000；t=11．9，P=0．000；t=5．09，P=0．000；t=5．20，P=0．000；t=3．60，P=0．000），且胸腔积液低于外周血（t=3．45，P=0．000；t=5．09，P=0．000；t=2．06，P=0．002），肺癌患者胸腔积液及外周血中TGF-β、IL-10水平高于正常对照组（t=13．38，P=0．000；t=5．2，P=0．000；t=16．14，P=0．000；t=8．07，P=0．000），且胸腔积液高于外周血（t=4．43，P=0．000；t=6．93，P=0．000）；而IFN-γ水平低于正常对照组（t=10．52，P=0．000；t=8．29，P=0．000），且胸腔积液低于外周血（t=2．70，P=0．004）。结论：肺癌患者胸腔积液及外周血CD4^＋CD25^＋调节T细胞水平及其抑制因子的升高，促进了肿瘤的进一步恶化。     

肺癌患者胸腔积液和外周血CD4^＋CD25^＋调节性T细胞与细胞因子表达及其意义的研究

目的：探讨肺癌患者胸腔积液及外周血CD4^＋CD25^＋调节性T细胞及其所分泌的细胞因子的特点及其临床意义。方法：采用流式细胞术和ELISA法检测32例肺癌患者胸腔积液及外周血CD4^＋CD25^＋调节T细胞水平、淋巴细胞亚群和TGF-β、IL-10以及IFN-γ的水平。结果：肺癌患者胸腔积液及外周血CD4^＋CD25^＋调节T细胞水平明显高于正常对照组（t=7．68，P=0．000；t=5．62，P=0．000），且胸腔积液高于外周血（t=2．05 P=0．002）；肺癌患者胸腔积液及外周血CD4、CD4／CD8、CD56阳性细胞比例明显低于正常对照组（t=7．51，P=0．000；t=3．63，P=0．000；t=11．9，P=0．000；t=5．09，P=0．000；t=5．20，P=0．000；t=3．60，P=0．000），且胸腔积液低于外周血（t=3．45，P=0．000；t=5．09，P=0．000；t=2．06，P=0．002），肺癌患者胸腔积液及外周血中TGF-β、IL-10水平高于正常对照组（t=13．38，P=0．000；t=5．2，P=0．000；t=16．14，P=0．000；t=8．07，P=0．000），且胸腔积液高于外周血（t=4．43，P=0．000；t=6．93，P=0．000）；而IFN-γ水平低于正常对照组（t=10．52，P=0．000；t=8．29，P=0．000），且胸腔积液低于外周血（t=2．70，P=0．004）。结论：肺癌患者胸腔积液及外周血CD4^＋CD25^＋调节T细胞水平及其抑制因子的升高，促进了肿瘤的进一步恶化。     

CD8~＋CD25~＋FOXP3~＋调节性T淋巴细胞在恶性胸腔积液中的表达及其临床意义

目的通过检测恶性胸腔积液中CD8＋CD25＋Foxp3＋调节性T淋巴细胞（T8reg）的表达,探讨其与恶性胸腔积液患者临床预后的关系。方法同步采集30例肺癌合并胸腔积液患者的胸腔积液和外周血,20例良性胸腔积液患者的胸腔积液和外周血,另采集20例健康对照者外周血,用流式细胞术检测上述标本中CD8＋CD25＋Foxp3＋T淋巴细胞的表型、百分比,分析其与恶性胸腔积液患者生存时间的关系。结果恶性胸腔积液组中T8reg占总CD8＋T细胞的比例显著高于良性胸腔积液组[（2.20±0.25）%vs（0.38±0.05）%,P=0.018],亦高于自身外周血组[（0.52±0.06）%,P=0.000],恶性胸腔积液患者外周血中T8reg的比例高于正常健康者外周血中的比例[（0.52±0.06）%vs（0.31±0.04）%,P=0.005]。而良性胸腔积液组胸腔积液、外周血（0.34±0.04）%与健康对照组外周血三组中T8reg细胞的数量占总CD8＋T细胞比例没有明显升高,差别没有统计学意义（P〉0.05）。T8reg高、低表达水平组患者的中位生存时间分别为105、195d,两者差异有统计学意义（P=0.004）。Cox回归模型多因素分析显示MPE中T8reg的表达水平、肿瘤大小是影响MPE患者预后的独立因素（P值分别为0.018、0.006）。结论肺癌伴胸膜转移患者的MPE及其外周血T8reg细胞的比例明显增高;MPE中T8reg细胞表达下降预示MPE患者生存率会明显改善,提示CD8＋CD25＋Foxp3＋T细胞在肺癌发生、发展的免疫病理过程中具有显著意义。     

大肠癌患者外周血OD4＋0D25＋CD127－调节性T细胞表达及其临床意义

目的：探讨OD4＋0D25＋CD127－调节性T细胞在大肠癌患者外周血中的表达水平及临床意义。方法：应用流式细胞仪检测200例大肠癌患者外周血OD4＋0D25＋CD127－调节性T细胞占CD4＋T细胞的百分比,并分析其与大肠癌组织的分化程度、淋巴结转移和临床分期的关系。结果：大肠癌患者外周血OD4＋0D25＋CD127－调节性T细胞占CD4＋T细胞的百分率[（4．84±1．35）％]明显高于健康对照组[（0．85±0．25）％],差异有统计学意义,P〈0．05。低分化者外周血调节性T细胞[（4．21±0．42）％]明显高于高分化者[（3．92±0．41）％],差异有统计学意义,P〈0．05;有淋巴结转移者外周血调节T细胞[（4．57±l_44）％]明显高于无淋巴结转移者[（2．36±0．68）％],差异有统计学意义,P〈0．01;Ⅲ和Ⅳ期患者外周血调节性T细胞[（3．53±1．41）％和（4．38±1．32）％]明显高于Ⅰ～Ⅱ期[（1．90±0．86）％],差异有统计学意义,P〈0．01。结论：大肠癌患者外周血OD4＋0D25＋CD127调节性T细胞占CD4＋T细胞的百分率明显升高,可能在大肠癌的免疫耐受和免疫逃逸中发挥重要作用,检测其结果对于判断大肠癌的病程进展及预后有一定参考价值。     

老年肺癌患者血清T淋巴细胞亚群CD28的检测及临床意义

目的：探讨老年肺癌患者淋巴细胞免疫功能状态、临床意义及与肺癌病理类型、临床分期的关系。方法：采用三色免疫荧光标记流式细胞术检测35名正常老年人及32例老年肺癌患者外周血的总T淋巴细胞（CD3^＋）、辅助／诱导T淋巴细胞（CD4^＋）、抑制／细胞毒T淋巴细胞（CD8^＋）、细胞毒T细胞（CD8^＋CD28^＋）和抑制T细胞（CD8^＋CD28）。结果：老年肺癌组CD4^＋Tz细胞（t=2．01,P〈0．05）和CD3^＋、CD8^＋T细胞及CD8^＋CD28^＋T细胞亚群明显低于老年正常对照组,t=2．01,P〈0．01;CD8^＋CD28T细胞亚群明显高于老年正常对照组,t=2．01,P〈0．01;老年肺癌患者中,T淋巴细胞及亚群CD28的表达在TNM临床分期及病理类型间差异均无统计学意义,t=2．11,P值均〉0．05。结论：老年肺癌患者存在明显的T淋巴细胞亚群免疫功能紊乱,抗肿瘤能力明显下降,并导致病情恶化更严重,且与病理类型及临床分期无关。     

食管癌患者CD4^＋ CD25^＋调节性T细胞的检测及意义

目的：探讨CD4^＋ CD25^＋调节性T细胞在食管癌局部及全身免疫中的作用。方法：流式细胞仪检测97例食管癌患者外周血和20例肿瘤组织的CD4^＋ CD25^＋调节性T细胞比例,比较不同病理类型、不同分期等食管癌患者外周血及肿瘤局部组织的CD4^＋ CD25^＋调节性T细胞的分布变化。结果：食管癌患者肿瘤组织CD4^＋ CD25^＋调节性T细胞比例为（18.97±2.38）%,高于患者外周血比例〔（17.57±3.99）%〕,差异无统计学意义,t=1.511,P〉0.05;食管癌患者肿瘤组织及外周血中CD4^＋ CD25^＋调节性T细胞占CD4＋ T淋巴细胞的比例,均高于同期健康对照组患者外周血的比例（9.35±1.41）%,差异有统计学意义,t值分别为12.111和8.332,P值均〈0.01。CD4^＋ CD25^＋调节性T细胞水平与临床分期（F=9.384）、有无淋巴结转移（t=2.326）有关,P值均〈0.05。结论：食管癌患者全身及肿瘤局部均存在免疫异常,推测CD4^＋ CD25^＋调节性T细胞可能参与了食管癌的发生与发展。     

化疗对肺癌患者外周血中CD4~＋ CD25~＋调节性T细胞数目的影响及意义

目的研究化疗药物对肺癌患者外周血中Treg（CD4＋ CD25＋调节性T细胞）的影响及意义。方法采集60例肺癌术后患者化疗前1天及化疗后第10天外周静脉血,应用流式细胞技术检测外周血中Treg细胞以及CD3＋、CD4＋、CD8＋T、NK细胞占T淋巴细胞百分比,CD4＋T/CD8＋T比值。结果化疗前NSCLC患者外周血CD4＋ CD25＋调节T细胞比率明显高于健康对照组（P〈0.05）;且Ⅳ期患者调节T细胞比率明显高于Ⅲ期患者（P〈0.05）。化疗后NSCLC患者外周血CD4＋ CD25＋调节T细胞较化疗前显著降低（P〈0.05）。化疗前后不同病理分型患者外周血中CD4＋CD25＋细胞变化差异无统计学意义。化疗后CD8＋T细胞占T淋巴细胞比例（28.129±10.900）%较化疗前（24.876±6.631）%升高（P〈0.05）。化疗后CD4＋/CD8＋（1.506±0.691）较化疗前（1.680±0.704）降低（P〈0.05）。结论肿瘤负荷可显著促进肺癌患者外周血Treg细胞分化,化疗后肺癌患者Treg细胞比例下降。     

肺癌患者外周血CD4~＋CD25~＋调节性T细胞检测的临床意义

目的：探讨肺癌患者外周血CD4＋CD25＋调节性T细胞（Treg）的比例变化及其在肿瘤发生发展中的作用。方法：应用流式细胞术检测78例肺癌患者和30例健康者CD4＋CD25＋Treg比例,分析其与肺癌的临床分期、病理类型、组织学分化程度及手术的关系。结果：肺癌患者外周血CD4＋CD25＋Treg比例与健康对照组比较,差异有统计学意义,t=2.316,P=0.04。Ⅲ、Ⅳ期肺癌患者Treg比例显著高于Ⅰ＋Ⅱ期患者,t值分别为2.205和2.207,P值均为0.04。鳞癌、腺癌、小细胞肺癌高、中和低分化肺癌患者Treg比例显著高于对照组,P＆lt;0.05。手术后的肺癌患者Treg比例为（14.38±3.82）%,显著低于手术前的（20.16±5.24）%,t=1.823,P=0.05。结论：肺癌患者外周血CD4＋CD25＋Treg水平明显升高,且与肺癌的进展密切相关,越晚期水平越高;手术后肺癌患者外周血CD4＋CD25＋Treg水平明显下调。     

胃癌组织中T细胞及其亚群ICOS分子的表达及其意义

目的探讨胃癌组织中T细胞共刺激分子ICOS及其亚群的表达及意义。方法应用流式细胞术检测38例胃癌和21例健康人（对照组）外周血T细胞亚群及其共刺激分子ICOS的表达。结果胃癌组与对照组比较：CD3^＋T细胞表达（53．61±13．84）／（72．07±7．83）％,P〈0．01;CD3^＋CD4^＋T细胞表达（29．84±9．71）／（38．79±5．08）％。P〈0．01;CD3^＋ICOS^＋T细胞表达（25．80±10．56）／（0．82±0．98）％,P〈0．01;CD3^＋CD8^＋ICOS^＋T细胞表达（1．57±1．99）／（0．02±0．04）％,P〈0．01;CD3^＋CD8^＋ICOS^-T细胞表达（16．06±6．94）／（20．56±6．54）％,P〈0．05。胃癌组患者手术前和手术后1周外周血T细胞亚群的差异无统计学意义（P〉0．05）。结论胃癌患者T细胞数量明显减少,T细胞共刺激分子ICOS表达增高,CD4^＋T细胞显著减少。     

胃癌组织中T细胞亚群及其ICOS分子的表达及意义

目的探讨胃癌组织中T细胞共刺激分子ICOS及其亚群的表达及意义。方法应用流式细胞术检测38例胃癌和21例健康人（对照组）外周血T细胞亚群及其共刺激分子ICOS的表达。结果胃癌组与对照组比较：CD3^＋T细胞表达（53．61±13．84）％和（72.07±7．83）％,P〈0．01;CD3^＋CD4^＋T细胞表达（29．84±9．71）％和（38．79±5．08）％,P〈0．01;CD3^＋ICOS^＋T细胞表达（25．80±10．56）％和（O．82±0．98）％,P〈0．01;CD3^＋CD8^＋ICOS^＋T细胞表达（1.57±1．99）％和（0．02±0．04）％,P〈0．01;CD3^＋CD8^＋ICOS^-T细胞表达（16．06±6．94）％和（20．56±6．54）％,P〈0．05。胃癌组患者手术前和手术后1周外周血T细胞亚群的差异无统计学意义（P〉0．05）。结论胃癌患者T细胞数量明显减少,T细胞共刺激分子ICOS表达增高,CIM’T细胞显著减少。     

Effector, memory and naïve CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients

The proportions of na?ve, memory and effector CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients were studied. CD8+ T subsets were identified by using a combination of the following antibodies: anti-CD45RA, anti-CD45RO, anti-CD27 and anti-CD28, as well as antibodies to other markers. Fas-positive cells were determined in each CD8+ T subset. Also, the intracellular cytokine patterns of CD4+ and CD8+ lymphocytes from pleural effusion were analysed. In na?ve, memory and effector CD8+ T subsets no significant differences were observed in peripheral blood between healthy donors and cancer patients. In contrast, a high proportion of cells with memory phenotype (CD45RA-CD45RO+CD27+CD28+) and a low proportion of cells with effector phenotype (CD45RA+CD45RO-CD27-CD28-) were found in pleural effusion with respect to peripheral blood (P<0.001). The altered proportions of CD8+ T subsets in pleural effusion were not mediated by type 2 cytokines produced by CD4+ or CD8+ lymphocytes. In the effector CD8+ T subset, from peripheral blood as well as from pleural effusion, a low percentage of perforin-expressing cells was observed compared to granzyme A-expressing cells. Additionally, a high percentage of na?ve CD8+ T cells expressing Fas was found. Our data suggest that: (i) terminal-differentiation process of CD8+ T cells is blocked, and (ii) early Fas-expression in CD8+ T cells, which was reflected even in peripheral blood, may lead to apoptosis of na?ve cells when they reach the effector stage. All these processes may contribute to the inadequate antitumour immune response found in lung carcinoma patients.     

CD4+CD25+调节性T细胞对晚期肺癌患者免疫抑制作用的研究

目的 探讨Treg及Th1/Th2类细胞因子在晚期肺癌肿瘤免疫抑制中的作用.方法 选取100例初治晚期肺癌患者及50例健康自愿者.采用流式细胞术检测其外周血中Treg、Th1类细胞因子(IFN-γ、IL-2、TNF-a)、Th2类细胞因子(IL-4、IL-6、IL-10)水平,同时分析CD4+CD25+Treg与Th1/Th2类细胞因子之间的相关性.结果 ①晚期肺癌患者外周血中Treg为(11.12±5.83)%,高于健康对照组(7.46±3.07)%,差异有统计学意义(P=0.003);②化疗前肺癌患者外周血中Treg为(11.12±5.83)%,明显高于化疗后(6.45±3.74)%,差异有统计学意义(P<0.001);③晚期肺癌患者与正常对照组Th1/Th2类细胞因子水平分别为:IFN-γ(8.56±3.62 vs 10.79±3.27,P=0.049)、IL-2(8.48±2.87 vs 10.22±4.03,P=0.03)、TNF-a(6.18±2.67vs8.14±2.87,P=0.007)、IFN-γ/IL-4(3.33±1.44 vs 4.09±1.00,P=0.028)、IL-4(3.17±1.19 vs 2.45±0.43,P<0.001)、IL-6(3.88±2.08 vs 2.33±0.88,P<0.001)、IL-10(3.64±1.73 vs 2.54±1.08,P=0.008),其中Th2类因子水平明显升高,差异有统计学意义(P均<0.05);④CD4+CD25+Treg与Th1类细胞因子IFN-γ、TNF-a、IL-2及IL-6无相关性(P均>0.05);与Th1/Th2(γ=-0.273,P=0.003)呈负相关;与Th2类细胞因子IL-4(γ=0.237,P=0.009)、IL-10(0.626,P<0.001)呈正相关(P均<0.05).结论 晚期肺癌患者CD4+CD25+Treg、Th2类细胞因子水平显著升高,Th1类细胞因子水平下降,它们共同导致肿瘤患者免疫抑制及肿瘤进展,监测其水平变化有助于判断肺癌患者疗效、预后,有效调控CD4+CD25+Treg及负性细胞因子水平可能是治疗肺癌的一个新策略.     

DC-CIK对胃癌合并腹水患者外周血CD4+CD25+调节性T细胞增殖及功能的影响

目的:探讨DC-CIK对胃癌合并腹水患者外周血CD4+CD25+调节性T胞(Treg细胞)比例及功能的影响。方法:60例胃癌合并腹水患者,于输注DC-CIK前1天及DC-CIK治疗结束后1周分别采集外周血。流式细胞术检测外周血Treg细胞的比例,RT-PCR法检测其Foxp3mRNA表达情况;将分选出的Treg细胞和CD4+CD25-T细胞分为单纯Treg细胞组（A组）、1∶1混合培养（B组）、单纯CD4+CD25-细胞组（C组）进行培养,3H-TdR掺入法检测Treg细胞抑制CD4+CD25-细胞增殖的能力。结果:治疗后外周血Treg细胞占CD4+T细胞的比例较疗前显著下降［(6.21±1.37)% vs (9.38±1.06)%,P＜0.05］。治疗后Treg细胞Foxp3mRNA表达水平较治疗前显著下降［(56.18±13.25)% vs (85.26±11.58)%,P＜0.05］。治疗后Treg对CD4+CD25-T细胞抑制增殖能力较治疗前明显下降［(37.31±4.16)% vs (48.92±5.25)%,P＜0.05］。结论:输注DC-CIK免疫治疗,可显著降低胃癌合并腹水患者外周血Treg细胞比例,下调Foxp3mRNA表达水平,降低Treg细胞免疫抑制功能,有利于诱导抗肿瘤免疫效应。     

Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)

We hypothesized that the increased percentages of Regulatory T (Treg) cells, as well as over expression of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) by lymphocyte subsets might be associated with lung cancer. Accordingly, peripheral blood of 23 new cases with non-small cell lung cancer (NSCLC) and 16 healthy volunteers were investigated, by follow cytometry, for the prevalence of CD4+CD25+FoxP3+ Treg cells as well as surface (sur-) and intracellular (In-) expression of CTLA-4 by the main lymphocyte subsets (CD4+, CD8+ and CD19+). Results indicated that NSCLC patients had an increased percentage of Treg cells than controls (7.9±4.1 versus 3.8±1.8, P=0.001). The proportion of Treg cells was observed to be increased by stage increase in patients (stage II=5.2±2.4, stage III=7.9±4.4, stage IV=12.0±2.2), and also significantly higher in metastatic than non-metastatic stages (12.0±2.2 versus 6.8±3.9, P=0.023). Increase of SurCTLA-4- as well as InCTLA-4-expressing lymphocytes in patients were observed in nearly all investigated subsets, but significant differences between patients and controls were observed about InCTLA-4+CD4+ lymphocytes (8.6±7.1 and 3.8±5.3 respectively, P=0.006) as well as SurCTLA-4+CD8+ lymphocytes (0.3±0.2 and 0.2±0.1 respectively, P=0.047). In conclusion, the results suggest that immunotherapy regimen targeting CTLA-4 and Treg cells might be beneficial in lung cancer patients.     

甲状腺肿瘤患者外周血CD+4 CDHi25 CDLo127 调节性T细胞的检测及其临床意义

 目的　分析甲状腺肿瘤患者外周血CD+4 CDHi25 CDLo127 调节性T细胞（Treg）比例及其变化规律,初步探讨甲状腺肿瘤免疫抑制机制,以及分化型甲状腺癌和结节性甲状腺肿发病机制之间可能存在的相关性。方法　采用流式细胞技术联合标记CD4、CD25、CD127,检测43例初治分化型甲状腺癌患者（分化型甲状腺癌组）、132例初治结节性甲状腺肿患者（结节性甲状腺肿组）及153名健康者（健康对照组）的外周血T细胞各亚群和Treg 的比例。结果　分化型甲状腺癌组[（6.48±1.49）%]及结节性甲状腺肿组[（6.23±1.67）%]患者CD+4 CDHi25 CDLo127 Treg 比例均高于健康对照组[（5.62±1.48）%],差异有统计学意义（P＜0.05）,而分化型甲状腺癌组及结节性甲状腺肿组之间,差异无统计学意义（P＞0.05）。结论　结节性甲状腺肿与分化型甲状腺癌患者外周血CD+4 CDHi25 CDLo127 Treg 比例较健康者均显著升高,提示CD+4 CDHi25 CDLo127 Treg 可能是甲状腺肿瘤患者免疫抑制的重要原因之一。     

Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma

Immunotherapy against a variety of malignancies, including pleural-based malignancies, has shown promise in animal models and early human clinical trials, but successful efforts will need to address immunosuppressive factors of the tumor and host, particularly certain cytokines and CD4(+) CD25(+) regulatory T cells (Treg). Here, we evaluated the cellular and cytokine components of malignant pleural effusions from 44 patients with previously diagnosed mesothelioma, non-small cell lung cancer (NSCLC), or breast cancer and found significant differences in the immune profile of pleural effusions secondary to mesothelioma vs. carcinoma. Although a high prevalence of functionally suppressive CD4(+) CD25(+) T cells was found in carcinomatous pleural effusions, mesothelioma pleural effusions contained significantly fewer CD4(+) CD25(+) T cells. Activated CD8(+) T cells in pleural fluid were significantly more prevalent in mesothelioma than carcinoma. However, there is clear patient-to-patient variability and occasional mesothelioma patients with high percentages of CD4(+) CD25(+) pleural effusion T cells and low percentages of CD8(+) CD25(+) pleural effusion T cells can be identified. Mesothelioma pleural effusions contained the highest concentrations of the immunosuppressive cytokine transforming growth factor (TGF)-beta. Thus, the contribution of cellular and cytokine components of immunosuppression associated with malignant pleural effusions varies by tumor histology and by the individual patient. These results have implications for the development of immunotherapy directed to the malignant pleural space, and suggest the need to tailor immunotherapy to overcome immunosuppressive mechanisms in tumor environments.     

Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin’s lymphoma patients

The role of tumor-infiltrating T cell subsets in the prognosis of non-Hodgkin's lymphoma (NHL) has previously been reported. In the present study, we investigated the prognostic significance of different T cell subsets in the peripheral blood of NHL patients. Immunophenotyping was performed on the peripheral blood samples of 45 patients with newly diagnosed B cell NHL using flow cytometry. The relationship between T cell subsets of CD4+, CD8+, CD3+CD25+, CD4+CD25+, CD4+CD25(high) [as T regulatory cells (T reg)], and the CD4/CD8 ratio with international prognostic index (IPI) and response to therapy was determined. The percentages of CD3+, CD4+, and CD8+?T cells in the peripheral blood of the patients were 49.1?±?20.3%, 23.6?±?11%, and 31.4?±?14.4%, respectively (CD4/CD8 ratio: 0.92?±?0.6). There were 4.2?±?3.2% T reg cells. A study of the percentage of T cells in relation to IPI score showed a higher proportion of CD3+CD25+, CD4+, and CD4+CD25+ cells in low-risk patients compared with intermediate/high risk groups (p?相似文献   

CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer

It is well known that immunosuppression may contribute to the progression and chemotherapy-resistance of cancer. Recent studies have demonstrated that lymphocytes with the phenotype of CD4+CD25+ regulatory T cells (T-regs) contribute to immune dysfunction in cancer patients, and a relative increase in CD4+CD25+ regulatory T cells is related to immunosuppression and tumor progression in patients with some malignancies. In the present study, we evaluated the prevalence of T-regs in the peripheral blood of patients with breast cancer and non-small cell lung cancer. The phenotype of lymphocyte CD4+CD25+ cells was analyzed in peripheral blood of patients with breast cancer (n=22) and non-small cell lung cancer (NSCLC) (n=17). The population of CD4+CD25+ cells in CD3+ and CD4+ cells was evaluated by flow cytometric analysis with triple-color staining. Patients with breast cancer did not have a higher percentage of CD4+CD25+ cells in the total CD3+ and CD4+ cells in their peripheral blood than healthy volunteers. In contrast, patients with recurrent NSCLC had significantly higher percentages of CD4+CD25+ cells in CD3+ (47.6%) and CD4+ (71.0%) than healthy volunteers (n=10) who had CD4+CD25+ cells in CD3+ (33.7%, p=0.02) and CD4+ (52.2%, p<0.03). The population of CD4+CD25+ T-regs in the peripheral blood of patients with non-small cell lung cancer was significantly higher than that in healthy volunteers but not in breast cancer patients. These findings suggest that the use of T-reg-targeted immunomodulatory therapy may be a more effective strategy for patients with non-small cell lung cancer than for those with breast cancer.